Poliomyelitis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Poliomyelitis - Pipeline Review, H1 2016

Poliomyelitis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Poliomyelitis - Pipeline Review, H1 2016
Published Jun 08, 2016
81 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Poliomyelitis - Pipeline Review, H1 2016, provides an overview of the Poliomyelitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Poliomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Poliomyelitis
- The report reviews pipeline therapeutics for Poliomyelitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Poliomyelitis therapeutics and enlists all their major and minor projects
- The report assesses Poliomyelitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Poliomyelitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Poliomyelitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Poliomyelitis pipeline depth and focus of Indication therapeutics
- Develop and design in

  
Source:
Document ID
GMDHC8182IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Poliomyelitis Overview91
Therapeutics Development102
  Pipeline Products for Poliomyelitis Overview101
  Pipeline Products for Poliomyelitis Comparative Analysis111
Poliomyelitis Therapeutics under Development by Companies122
Poliomyelitis Therapeutics under Investigation by Universities/Institutes141
Poliomyelitis Pipeline Products Glance153
  Late Stage Products151
  Clinical Stage Products161
  Early Stage Products171
Poliomyelitis Products under Development by Companies181
Poliomyelitis Products under Investigation by Universities/Institutes191
Poliomyelitis Companies Involved in Therapeutics Development2017
  Beijing Minhai Biotechnology Co., Ltd201
  Beijing Tiantan Biological Products Co., Ltd.211
  Bharat Biotech International Limited221
  Bilthoven Biologicals B.V.231
  Biological E. Limited241
  Boryung Pharmaceutical Co., Ltd.251
  Codagenix, Inc.261
  Daiichi Sankyo Company, Limited271
  Grifols, S.A.281
  Johnson &Johnson291
  LG Life Science LTD.301
  Nanolek, LLC311
  Panacea Biotec Limited321
  Sanofi Pasteur SA331
  Sentinext Therapeutics Sdn Bhd341
  Sinovac Biotech Ltd.351
  Taiga Biotechnologies, Inc.361
Poliomyelitis Therapeutics Assessment378
  Assessment by Monotherapy Products371
  Assessment by Combination Products381
  Assessment by Target392
  Assessment by Route of Administration412
  Assessment by Molecule Type432
Drug Profiles4528
  (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile451
    Product Description451
    Mechanism of Action451
    R&D Progress451
  (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile461
    Product Description461
    Mechanism of Action461
    R&D Progress461
  (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile471
    Product Description471
    Mechanism of Action471
    R&D Progress471
  (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile481
    Product Description481
    Mechanism of Action481
    R&D Progress481
  (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile491
    Product Description491
    Mechanism of Action491
    R&D Progress491
  (diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile501
    Product Description501
    Mechanism of Action501
    R&D Progress501
  (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile511
    Product Description511
    Mechanism of Action511
    R&D Progress513
  immune globulin (human) - Drug Profile541
    Product Description541
    Mechanism of Action541
    R&D Progress542
  ImmunoRx - Drug Profile561
    Product Description561
    Mechanism of Action561
    R&D Progress561
  IPVGVI-3000 - Drug Profile571
    Product Description571
    Mechanism of Action571
    R&D Progress571
  LBVC - Drug Profile581
    Product Description581
    Mechanism of Action581
    R&D Progress581
  LBVD - Drug Profile591
    Product Description591
    Mechanism of Action591
    R&D Progress591
  polio (monovalent) vaccine - Drug Profile601
    Product Description601
    Mechanism of Action601
    R&D Progress601
  polio (virus like particle, bivalent) vaccine - Drug Profile611
    Product Description611
    Mechanism of Action611
    R&D Progress611
  polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile621
    Product Description621
    Mechanism of Action621
    R&D Progress621
  polio [serotypes 1, 2, 3] (monovalent) vaccine - Drug Profile631
    Product Description631
    Mechanism of Action631
    R&D Progress631
  polio [strain Sabin] vaccine - Drug Profile641
    Product Description641
    Mechanism of Action641
    R&D Progress641
  polio vaccine - Drug Profile651
    Product Description651
    Mechanism of Action651
    R&D Progress651
  polio vaccine - Drug Profile661
    Product Description661
    Mechanism of Action661
    R&D Progress661
  polio vaccine - Drug Profile671
    Product Description671
    Mechanism of Action671
    R&D Progress671
  polio vaccine - Drug Profile681
    Product Description681
    Mechanism of Action681
    R&D Progress681
  polio vaccine - Drug Profile691
    Product Description691
    Mechanism of Action691
    R&D Progress691
  polio vaccine 2 - Drug Profile701
    Product Description701
    Mechanism of Action701
    R&D Progress701
  poliomyelitis vaccine - Drug Profile711
    Product Description711
    Mechanism of Action711
    R&D Progress711
  VN-0105 - Drug Profile721
    Product Description721
    Mechanism of Action721
    R&D Progress721
Poliomyelitis Recent Pipeline Updates731
Poliomyelitis - Dormant Projects741
Poliomyelitis Discontinued Products751
Poliomyelitis Product Development Milestones764
  Featured News &Press Releases761
    Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur s Investigational Pediatric Hexavalent Vaccine761
    Mar 03, 2014: Inactivated Polio Vaccines Broadly Available for the World's Children in the Drive Toward Polio Eradication771
    Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima771
    Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine781
    Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets782
Appendix802
  Methodology801
  Coverage801
  Secondary Research801
  Primary Research801
  Expert Panel Validation801
  Contact Us801
  Disclaimer811

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Poliomyelitis - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Poliomyelitis-Pipeline-Review-H1-2016-2088-15914>
  
APA:
Global Markets Direct - Market Research. (2016). Poliomyelitis - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Poliomyelitis-Pipeline-Review-H1-2016-2088-15914>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.